The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Re-differentiation of radioiodine-refractory BRAF V600E-mutant thyroid carcinoma with dabrafenib: A pilot study.
Stephen M. Rothenberg
No relevant relationships to disclose
David G McFadden
No relevant relationships to disclose
Edwin Palmer
No relevant relationships to disclose
Gilbert H Daniels
No relevant relationships to disclose
Lori J. Wirth
No relevant relationships to disclose